Skip to main content

Table 2 Mean absorbed organ doses from α-RIT with 211At-labeled A11 minibody

From: Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

 

Mean absorbed dose (Gy/MBq)

Organ

Without NaClO4

With NaClO4 c

Blood

4.7

4.8

Bone Marrowa

1.3

1.4

Heart

1.5

1.5

Lungs

3.3

2.4

Salivary glands

5.0

0.9

Throat

4.7

2.1

Thyroidb

64.7

27.5

Stomach

5.6

1.4

Liver

1.9

1.6

Spleen

2.8

1.3

Kidneys

2.1

1.7

Muscle

0.3

0.3

Small intestine

1.2

0.8

Large intestine

0.9

0.6

Bladder

2.8

1.8

Tumor

2.2

1.9

Prostate

2.4

1.5

  1. aDose to bone marrow was estimated using a bone marrow-to-blood-ratio of 0.29
  2. bDose to thyroid was estimated from the throat (assuming that all activity was located in thyroid and using a standard weight of 3 mg)
  3. cDose corresponding to pre-treatment with NaClO4 , using biodistribution data measured at 5 hpi and 9 hpi, complemented with theoretically calculated data for 1, 23 and 42 hpi